Study of CAR T-cell therapy rese-cel in scleroderma enrolling in US
A Phase 1/2 trial testing Cabaletta Bio’s CAR T-cell therapy, rese-cel (resecabtagene autoleucel), in adults with hard-to-treat systemic sclerosis (SSc) is recruiting patients at several sites in the U.S. The open-label RESET-SSc trial (NCT06328777) is assessing the safety and efficacy of rese-cel as a single infusion into…